Factors Associated with Medication Adherence for People Living with Acute HIV Infection in a Tertiary Chinese Hospital in Beijing

Xiaolan Wang,1 Dongmei Li,1 Meixia Gao,1 Yuefang Zhou,1 Caiping Guo,1 Tong Zhang,1 Lili Zhang2, and Wen Wang1

1Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China
2Department of Nursing, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China

Correspondence should be addressed to Lili Zhang; zhanglili2020@mail.ccmu.edu.cn and Wen Wang; wangwen2020@ccmu.edu.cn

Received 29 June 2020; Revised 27 December 2020; Accepted 31 December 2020; Published 6 January 2021

Academic Editor: Caijun Sun

Copyright © 2021 Xiaolan Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Both the management and caregiving intervention of people living with HIV (PLWH), especially during acute HIV-1 infection, represent a public health issue and a form of social support. This current study analyzed the demographic and clinical factors associated with antiretroviral therapy (ART) adherence of PLWH from positive HIV diagnosis to ART initiation in a tertiary Chinese hospital in Beijing. A total of 200 participants diagnosed with acute HIV-1 infection were enrolled in this study. We collected demographic and clinical data by the use of a self-reported questionnaire. Bivariate and multivariate logistic regressions were used to determine associations between potential variables and outcomes. We found that medication adherence was impacted by years of ART and number of reminders (all $P<0.05$). In addition, medication adherence was associated with viral load at 48 weeks ($P=0.035$). Future studies are needed to investigate effective interventions that could facilitate ART adherence.

1. Introduction

The total number of people living with HIV (PLWH) and acquired immunodeficiency syndrome (AIDS) was 831 225 by the end of July 2018 in China [1]. The number of men who have sex with men (MSM) infected with HIV continues to increase in China [2–6]. In China, rapid upward trends occurred in the proportion of HIV-1-infected MSM, the percentages of which increased by 7.3%, 12.2%, 29.4%, and 25.8% in 2005, 2007, 2011, and 2014, respectively, suggesting that the MSM now constitute the population in which HIV-1 transmission is rapidly increasing [4, 6–9]. There is a large number of MSM in Beijing, one of the most MSM-friendly cities in China, although the spread of HIV/AIDS through sexual contact also increased from 87.1% in 2011 to 96.9% at the end of 2016 in this city [10]. Acute HIV-1 infection is associated with a rapid rise in HIV plasma viremia and commonly manifested with clinically reported symptoms of fever, headache, etc. [11]. Definitions of acute, early, or chronic infection have been demonstrated using the evolution of HIV plasma viremia and HIV-specific antibody [12–15]. Acute and early HIV-1 infection is a major contributor to the epidemic spread of HIV and limiting this spread through “test and treat” strategies may require treatment of persons during the acute phase of infection [11, 16, 17]. Intervention during this stage of infection can dramatically reduce HIV transmission [12, 18–20]. Therefore, the management and care of PLWH, especially during acute HIV-1 infection, are both a public health and social issue. It is very important to understand the demographic and clinical factors affecting the increased HIV epidemic of MSM in Beijing and to promote HIV testing, prevention counseling, and other health care and social services that could reduce HIV and STI transmission.

Antiretroviral therapy (ART) has been shown to be effective in reducing viral loads in PLWH, virus infectivity, and both morbidity and mortality of AIDS-related diseases [21,
In the effort to end the HIV/AIDS epidemic by 2030, the World Health Organization (WHO) updated the ART guidelines in 2015, and all PLWH worldwide were recommended to receive ART as early as possible, regardless of CD4 T-cell count or WHO clinical stage [21]. In 2017, of the 37.9 million PLWH, 24.5 million had access to ART, representing an important milestone in the fight against HIV/AIDS; however, there remains a large gap between the reported percentage and 90% adherence, as the estimated adherence ranges from 55.7% to 85.9% in China [21, 23–25]. China’s National Free Antiretroviral Treatment Program (NFATP) was initiated as a pilot in 2003, and enormous efforts have been made to improve the capability to treat the large number of PLWH in China [26, 27]. However, adherence to ART is a complex behavior that is influenced by many demographic and clinical factors, including availability of reminders, substance use, dietary diversity, CD4 T-cell count, depressive symptoms, adverse effects of ART, duration of ART, etc. [28–33]. Thus, the prevention of PLWH from loss to follow-up and the maintenance of optimal ART adherence remain major challenges in China [34–36].

Despite increasing evidence of the importance of engagement in care, little is known about the characteristics of people living with HIV acute infection and factors associated with their antiretroviral medication adherence. Here, in this study, we analyzed the medication adherence of 200 people living with acute HIV infection in a tertiary Chinese hospital in Beijing. This study is aimed at providing empirical evidence for interventions for people living with acute HIV infection.

2. Methods

2.1. Study Subjects. In this study, participants were enrolled from the Beijing PRIMO cohort or were living with acute HIV infection but were not included in the PRIMO cohort since the initiation of the main cohort. The PRIMO cohort is a prospective clinical cohort of uninfected MSM to identify acute HIV infection at Beijing Youan Hospital, a tertiary Chinese hospital in Beijing, China [9]. After enrollment, the participants were screened for plasma HIV-1 antibody, HIV-1 RNA level, and clinical signs of acute infection, syphilis, and HBV/HCV coinfection status. They were then followed up every 2 months, and HIV-1 antibody was detected at each visit. AHI was defined as a negative or indeterminate HIV-1 antibody status but a positive HIV RNA status [37]. Moreover, people living with acute HIV were identified and then treated under early ART with tenofovir disoproxil fumarate (TDF), lamivudine (3TC), and efavirenz (EFV), all of which are recommended as a first-line regimen in China. In addition, their health status was monitored at each visit at 1, 2, 4, 8, and 12 weeks and every 3 months thereafter. Acute/early HIV-1 infection was classified according to the Fiebig stages based on the characteristics of PLWH [15]. At baseline, 200 eligible participants were identified at Fiebig stage III–VI. Participants were at least 20 years of age, received ART one year after the diagnosis of HIV acute infection, provided written informed consent, voluntarily participated in this study, and were capable of clear awareness and normal expression. Excluded participants were those who suffered from cognitive disorder, oral expression deficiency, mental diseases, or presented with other severe chronic diseases.

2.2. Measurements of Independent Variables and Outcomes. All independent variables, including age, level of education, employment, ART reminders, source of assistance, first closure target, years of ART, mental health and marital status, were self-reported by all included participants. All independent variables were categorized as two or three kinds to satisfy the requirement of statistical power. Medication adherence was defined as a dichotomized outcome (more than one pill missed or no pill missed in the previous month).

2.3. Statistical Analysis. We generated sample characteristics of participants. We performed a descriptive analysis and assessed bivariant associations between our outcome variable (medication

Table 1: Baseline characteristics of participants.

|                          | Missed medication | Unmissed medication |
|--------------------------|-------------------|---------------------|
| Age                      |                   |                     |
| 20–30                    | 6 (18.2)          | 75 (46.3)           |
| 30–50                    | 24 (72.7)         | 81 (50)             |
| 50 and more              | 3 (9.1)           | 6 (3.7)             |
| Level of education       |                   |                     |
| High school or below     | 18 (54.5)         | 83 (49.7)           |
| College or above         | 15 (45.5)         | 84 (50.3)           |
| Employment               |                   |                     |
| Employed or self-employed| 19 (57.6)         | 120 (76.4)          |
| Unemployed or student    | 14 (42.4)         | 37 (23.6)           |
| Marital status           |                   |                     |
| Married                  | 14 (43.8)         | 37 (22.6)           |
| Unmarried or widowed or divorced | 18 (56.3) | 127 (77.4) |
| Years on ART             |                   |                     |
| One-three                | 5 (17.9)          | 81 (73.6)           |
| Three or more            | 23 (82.1)         | 29 (26.4)           |
| Number of reminders      |                   |                     |
| No                       | 23 (67.6)         | 8 (4.9)             |
| One                      | 6 (17.6)          | 135 (83.3)          |
| Two or more              | 5 (14.7)          | 19 (11.7)           |
| First disclosure target  |                   |                     |
| Family members           | 11 (34.4)         | 65 (45.1)           |
| Friends or sex partner   | 11 (34.4)         | 51 (35.4)           |
| Other                    | 10 (31.3)         | 28 (19.4)           |
| Number of assistance sources |              |                     |
| No                       | 17 (50)           | 55 (33.5)           |
| One                      | 12 (35.3)         | 67 (40.9)           |
| Two or more              | 5 (14.7)          | 42 (25.6)           |
| Mental health            |                   |                     |
| Very good/good           | 23 (67.6)         | 110 (68.8)          |
| Very bad/bad/fair        | 11 (32.4)         | 50 (31.3)           |
adherence) and potential predictors using logistic regression tests. Variables significant in bivariable analysis ($P < 0.05$) were incorporated into a multivariable logistic regression model. In addition, we also compared the CD4 and viral suppression rates at each time point between the missed and unmissed groups. All analyses were conducted by SPSS version 22.0 (IBM Corp. 2013).

### 3. Results

#### 3.1. General Characteristics of the Study Participants

In this study, at baseline, 200 eligible PLWH were ultimately selected and enrolled in the intervention group. Two hundred questionnaires were distributed and collected, with a response rate of 100%. All PLWH were infected by unprotected sexual behavior. The majority of PLWH were between 30 and 50 years old, with a median age of 33.07 years. PLWH were mostly single, with a high school or below level of education, were self-reported staff workers, and were migrants from other cities (Table 1).

#### 3.2. Factors Associated with Medication Adherence

Among all the participants, 17.2% missed ART. The final multivariable model suggested that participants who were subjected to ART for more than three years had significantly higher odds of missed medication (Table 2). Conversely, using more reminders had significantly lower odds of missed medication.

#### 3.3. Association between Medication Adherence, CD4 T-Cell Count, and Viral Load

No between-group differences in CD4 T-cell counts at any point were observed. However, between-group differences in viral suppression rate at 48 weeks were detected ($P = 0.035$). The detailed information is provided in Table 3.
4. Discussion

Current ART has transformed HIV/AIDS from an acute, often lethal disease to a chronic disease, leading to an average life expectancy comparable to that of healthy persons [38]. However, ART adherence is crucial for the quality of life of PLWH, and this mostly depends on influences from the various sources, including material and mental health support from their family, spouse, partner, or friends [29, 30, 39]. Hence, it is very important to investigate the social support, social care, and strategies of implementation towards this PLWH population [34, 35, 40]. Therefore, we examined the characteristics of PLWH during acute infection and the influence of demographic and clinical factors on ART adherence. To our knowledge, this study is one of the first efforts to investigate the accuracy of ART adherence among people living with acute HIV in China using a large Beijing PRIMO cohort.

Years of ART emerge as one of the significant contributors to the odds of missed medication. Participants experiencing a relatively higher number of years of ART may encounter several concurrent barriers towards medication adherence. The cumulative side effects of ART may be associated with a lower level of perspective memory performance, which is a key to medication adherence [41, 42]. The situation may be getting even worse as participants get older due to the combination pathology of aging and HIV infection [43]. Another barrier that participants may face is hopelessness. Participants may feel that they have lost control of their life and experience low self-efficacy, which may also be related to increased odds of missed medication [44, 45]. Interventions should be tailored to address concurrent side effects of ART and hopelessness.

PLWH should have the option to have more reminders for medication. The study showed statistical significance between the number of reminders and medication adherence, indicating that those using more reminders tend to have lower odds of missed medication. This reflects a compensatory mechanism of cognitive deficit in many HIV-positive participants. Therefore, emphasis should be made to hold discussions with patients to work together to find the most suitable reminder of medication. These patients should be taught practical skills concerning medicine management to avoid missing medication, overcome side effects of medicine, and develop a life habit that includes taking medicine [46]. Interventions aimed at improving medication adherence conducted in older adults living with chronic disease could be transferred to the field of HIV care. For example, a meta-analysis summarizing the effectiveness of the teach-back method found that this method not only can improve adherence but also can positively affect self-efficacy [47]. Other methods, such as patient education (e.g., recurrent and personalized telephone counseling sessions with health educators), medication regimen management (using combinatory pills to reduce the number of pills patients take daily), clinical pharmacist consultation for chronic disease comanagement, cognitive behavioral therapies, medication reminders, and incentives to promote adherence, should be integrated into routine care of HIV participants [48].

In addition, we found that missed medication was associated with a reduced suppression rate at week 48. However, we did not longitudinally explore this association. Therefore, future longitudinal studies are needed to verify the temporal relationship between medication adherence and HIV clinical outcomes.

Several limitations should also be addressed: (1) the nature of the cross-sectional study from which we could not draw temporal relationships between potential variables and outcomes; (2) the small sample size, which could cause selection bias; and 3) the missing variables that limited our ability to draw a more comprehensive picture. Future studies with large sample sizes and multiple waves are needed to address these limitations.

5. Conclusions

This study revealed that medication adherence is impacted by various factors, such as years of ART and number of reminders. Future studies are needed to investigate effective interventions that could facilitate ART adherence.

Data Availability

The dataset used and/or analyzed during the current study is available from the corresponding author on reasonable request.

Ethical Approval

The study followed the principles outlined according to the Declaration of Helsinki. It was emphasized that participation was voluntary and could be terminated at any time during the study. At enrollment, all subjects provided baseline demographic, clinical, and epidemiological information by completing a standardized questionnaire. This study has been approved by the Beijing Youan Hospital Research Ethics Committee (No. 2014-24). The methods were carried
out in accordance with approved guidelines and regulations. The participants were also assured of confidentiality.

**Consent**

The patients received both written and oral information about the study before they gave their informed consent.

**Disclosure**

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**Authors’ Contributions**

X.W., L.Z., and W.W. conceived and designed the study. D.L., M.G., Y.Z., C.G., and T.Z. collected the patient information and contributed to technical support. X.W., D.L., T.Z., L.Z., and W.W. analyzed the data. X.W., L.Z., and W.W. wrote the manuscript. All authors read and approved the final manuscript. Xiaolan Wang and Dongmei Li contributed equally to this work.

**Acknowledgments**

We thank Pr. Bin Su at the Beijing Key Laboratory for HIV/AIDS Research for his valuable comments on the draft of the manuscript and for his unreserved support. We would like to extend our appreciation to the 200 participants of this survey, and especially, the social volunteers, nurses, and clinicians who contributed dramatically to the process of data collection and social support and care giving to PLWH. This work was supported by the Beijing Municipal Administration of Hospitals (PG20181703 to X.W.), the National 13th Five-Year Grand Program on Key Infectious Disease Control (2017ZX10202101-004 to T.Z., 2017ZX10202101-001-004 to W.W., and 2018ZX10715-005-002-002 to C.G.), the Beijing Municipal of Science and Technology Major Project (Z191100007619047 to L.Z., DI611000004160005 to C.G.), and the China Primary Fund Health Care Foundation-Youan Medical Development Fund (BJYAYY-2020GL-01 to L.Z.).

**References**

[1] NCAIDS, NCSTD, China CDC, "Update on the AIDS/STD epidemic in China the third quarter of 2018," *Chinese Journal of AIDS & STD*, vol. 24, p. 1075, 2018.

[2] World Health Organization (WHO), Global Health Observatory (GHO) data, 2018, http://www.who.int/gho/hiv/en/.

[3] J. Zhao, L. Chen, A. Chaillon et al., "The dynamics of the HIV epidemic among men who have sex with men (MSM) from 2005 to 2012 in Shenzhen, China," *Scientific reports*, vol. 6, p. 28703, 2016.

[4] H. Shang and L. Zhang, "MSM and HIV-1 infection in China," *National Science Review*, vol. 2, pp. 388–391, 2015.

[5] Y. Feng, K. Bu, M. Li, X. Zhang, S. Jin, and L. Wang, "Meta-analysis of HIV infection incidence and risk factors among men who have sex with men in China," *Chinese Journal of Epidemiology*, vol. 7, pp. 752–758, 2015.

[6] H. Shang, J. Xu, X. Han, J. Spero Li, K. C. Arledge, and L. Zhang, "HIV prevention: bring safe sex to China," *Nature*, vol. 485, pp. 576–577, 2012.

[7] X. Wang, Z. Wang, X. Jiang et al., "A cross-sectional study of the relationship between sexual compulsivity and unprotected anal intercourse among men who have sex with men in Shanghai, China," *BMC infectious diseases*, vol. 18, p. 465, 2018.

[8] X. Mao, Z. Wang, Q. Hu et al., "HIV incidence is rapidly increasing with age among young men who have sex with men in China: a multicentre cross-sectional survey," *HIV Medicine*, vol. 19, no. 8, pp. 513–522, 2018.

[9] X. Huang, S. Lodi, Z. Fox et al., "Rate of CD4 decline and HIV-RNA change following HIV seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts," *Journal of Acquired Immune Deficiency Syndromes*, vol. 62, pp. 441–446, 2013.

[10] Beijing health and Family Planning Commission, Beijing Center for Disease Control and Prevention. Report on the HIV/AIDS epidemic 2016 in Beijing, 2016, http://www.bjcdc.org/article/ztbd/2016/12/4028a8db57d987e60158b95010c3052b.html.

[11] M. L. Robb, L. A. Eller, H. Kibuuka et al., “Prospective study of acute HIV-1 infection in adults in East Africa and Thailand,” *The New England Journal of Medicine*, vol. 374, pp. 2120–2130, 2016.

[12] M. L. Robb and J. Ananworanich, “Lessons from acute HIV infection,” *Current Opinion in HIV and AIDS*, vol. 11, pp. 555–560, 2016.

[13] W. C. Miller, N. E. Rosenberg, S. E. Rutstein, and K. A. Powers, “Role of acute and early HIV infection in the sexual transmission of HIV,” *Current Opinion in HIV and AIDS*, vol. 5, pp. 277–282, 2010.

[14] M. S. Cohen, C. L. Gay, M. P. Busch, and F. M. Hecht, "The detection of acute HIV infection," *The Journal of Infectious Diseases*, vol. 202, Suppl 2, pp. S270–S277, 2010.

[15] E. W. Fiebig, D. J. Wright, B. D. Rawal et al., "Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection," *AIDS*, vol. 17, pp. 1871–1879, 2003.

[16] B. G. Brenner, M. Roger, J. P. Routy et al., "High rates of forward transmission events after acute/early HIV-1 infection," *The Journal of Infectious Diseases*, vol. 195, pp. 951–959, 2007.

[17] M. J. Wawer, R. H. Gray, N. K. Sewankambo et al., "Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda," *The Journal of Infectious Diseases*, vol. 191, pp. 1403–1409, 2005.

[18] E. D. Kroon, N. Phanuphak, A. J. Shattock et al., "Acute HIV infection detection and immediate treatment estimated to reduce transmission by 89% among men who have sex with men in Bangkok," *Journal of the International AIDS Society*, vol. 20, p. 21708, 2017.

[19] M. S. Cohen, M. K. Smith, K. E. Muesing, T. B. Hallett, K. A. Powers, and A. D. Kashuba, "Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?," *Lancet*, vol. 382, pp. 1515–1524, 2013.
